Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCA16-DOTAY
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CCA16-DOTAY is a clearing agent (CA) used as a critical component in DOTA-based Pretargeted Radioimmunotherapy (DOTA-PRIT) regimens. It is a 500-kDa aminodextran polymer scaffold conjugated to approximately 16 DOTA-Yttrium (stable Y-89) complexes. In the PRIT workflow, CCA16-DOTAY is administered intravenously after a bispecific antibody (BsAb) has localized to the tumor but before the administration of a radiolabeled hapten (such as [177Lu]Lu-DOTA-Bn or [225Ac]PrDOTA). Its primary function is to bind to the circulating, unbound BsAb and facilitate its rapid hepatic clearance. By removing the BsAb from the blood pool, CCA16-DOTAY prevents the radiolabeled hapten from binding to circulating antibody, thereby reducing off-target radiation exposure and significantly improving the tumor-to-background targeting ratio. This agent has been extensively utilized in preclinical mouse xenograft models for cancers expressing HER2 (breast, gastric, and ovarian) and GPA33 (colorectal).
- Other names
- Dextran-DOTA-Yttriumclearing agent CCA16-DOTAY
Beyond the preview
Go deeper on CCA16-DOTAY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCA16-DOTAY.